BMRA earnings: next report 2026-08-27, real EPS beat/miss history, analyst consensus Buy, P/E -1.50. Updated 2026-07-23.
Biomerica (BMRA) Research Hub
Biomerica (BMRA) trades on NASDAQ, US in the Healthcare (Medical - Devices) sector. As of 2026-09-11, shares last closed at 2.24 USD (-1.32%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.50, market cap 0.01B. This hub links to the full technical, earnings and options research available for BMRA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Devices) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.24 USD (-1.32%) |
| 52-week range | 1.45 USD – 2.38 USD |
| Trend regime | Range |
| 14-day RSI | 73 (Overbought) |
| Trailing P/E | -1.50 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-27 |
Available research for BMRA
Covered Call on BMRA: how it works, illustrative setup around the real 2.24 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on BMRA: how it works, illustrative setup around the real 2.24 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on BMRA: how it works, illustrative setup around the real 2.24 USD price, max profit/loss, breakeven and when to use it. Educational.
BMRA technical analysis: range, last 2.24 USD, RSI 73, 52w range 1.45 USD–2.38 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is BMRA in?
Biomerica (BMRA) is classified under Healthcare (Medical - Devices), listed on NASDAQ, US.
Is BMRA in an uptrend or downtrend?
As of 2026-09-11, BMRA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is BMRA's trailing P/E ratio?
BMRA's trailing P/E is -1.50, with a market cap of 0.01B. See the earnings research page for full valuation detail.
When does BMRA next report earnings?
BMRA is next scheduled to report earnings on 2026-08-27, with a consensus EPS estimate of -1.2 USD.